AcuCort

AcuCort Equity

The The Equity of AcuCort (ACUC.SL) as of Oct 17, 2026 is 40.85 M SEK. In the previous year, The Equity was 47.53 M SEK — a change of -14.06% (lower).

Equity

40.85 MSEK

YoY

-14.06%

Last updated:

In 2024, AcuCort's equity was 40.85 M SEK, a -14.06% increase from the 47.53 M SEK equity in the previous year.

The AcuCort Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2017
29.75 M SEK
Jan 1, 2018
34.51 M SEK
Jan 1, 2019
53.97 M SEK
Jan 1, 2020
46.20 M SEK
Jan 1, 2021
60.37 M SEK
Jan 1, 2022
45.58 M SEK
Jan 1, 2023
47.53 M SEK
Jan 1, 2024
40.85 M SEK
The AcuCort Equity history
YEAREquityYoY
40.85 MSEK-14.06%
47.53 MSEK+4.28%
45.58 MSEK-24.50%
60.37 MSEK+30.67%
46.20 MSEK-14.39%
53.97 MSEK+56.37%
34.51 MSEK+16.00%
29.75 MSEK+26.20%
23.58 MSEK+19.51%
19.73 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AcuCort Stock analysis

What does AcuCort do? AcuCort AB is a pharmaceutical company based in Lund, Sweden, operating within the Health Care sector. The company focuses on the development, marketing, and sale of oral dissolvable films, specifically targeting medical applications. Its primary product, ISICORT, utilizes dexamethasone, a glucocorticoid, for treating acute allergic reactions and managing nausea and vomiting associated with chemotherapy. AcuCort AB has a small operational footprint, employing four full-time staff members. The company completed its initial public offering (IPO) on April 24, 2017, and is listed under the ticker ACUC.SL with ISIN SE0009695927. It maintains a website at https://acucort.se/ for further information. AcuCort AB operates predominantly in the Nordic region, with its headquarters situated in Lund, Skåne. The company's business model centers on the production and distribution of specialized pharmaceutical products designed to address specific medical needs. While details about its financial performance, market share, or additional product lines are not provided, the company's focus remains on its core product and regional market presence. Its operational scale reflects a startup or early-stage pharmaceutical enterprise with limited resources. The company's website serves as the primary source for updates and corporate information. AcuCort AB's activities are confined to the development and commercialization of oral film technology, emphasizing targeted therapeutic applications in healthcare. AcuCort is one of the most popular companies on Eulerpool.

Equity Details

Analyzing AcuCort's Equity

AcuCort's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding AcuCort's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating AcuCort's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

AcuCort's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in AcuCort’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about AcuCort stock

The Equity of AcuCort is 40.85 M SEK in 2024.

The Equity of AcuCort changed from 47.53 M SEK to 40.85 M SEK, representing a -14.06% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity AcuCort since 2006 – with annual values, charts, and detailed analysis.

The Equity's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's AcuCort historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — AcuCort

All Key Metrics — AcuCort